-
Tytuł:
-
Extensively drug-resistant tuberculosis: are we learning from history or repeating it?
-
Autorzy:
-
Dukes Hamilton C; Duke University School of Medicine, Durham, NC 27710, USA. />Sterling TR
Blumberg HM
Leonard M
McAuley J
Schlossberg D
Stout J
Huitt G
-
Źródło:
-
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2007 Aug 01; Vol. 45 (3), pp. 338-42. Date of Electronic Publication: 2007 Jun 22.
-
Typ publikacji:
-
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Jan. 2011- : Oxford : Oxford University Press
Original Publication: Chicago, IL : The University of Chicago Press, c1992-
-
MeSH Terms:
-
Drug Resistance, Bacterial*
Tuberculosis/*drug therapy
Developing Countries ; Humans ; Public Health ; Tuberculosis/epidemiology ; Tuberculosis/prevention & control ; United States/epidemiology
-
Grant Information:
-
AI051409 United States AI NIAID NIH HHS; D43TW007124 United States TW FIC NIH HHS; K24 AI001833 United States AI NIAID NIH HHS
-
Entry Date(s):
-
Date Created: 20070630 Date Completed: 20070817 Latest Revision: 20071114
-
Update Code:
-
20240104
-
DOI:
-
10.1086/519292
-
PMID:
-
17599311
-
Tuberculosis (TB) is an enormous global public health problem. Cases of extensively drug-resistant TB (XDR-TB) are being reported in increasing numbers across the globe. A large outbreak of XDR-TB associated with rapid and nearly universal mortality has been reported among patients with human immunodeficiency virus infection or acquired immunodeficiency disease in South Africa who have been receiving standard TB therapy and antiretrovirals. Epidemiologic features of this outbreak make it highly suspicious for health care-associated transmission. We urge the Infectious Diseases Society of America and its members to increase involvement in ongoing international TB prevention and treatment efforts and to develop a registry of experts in infection control and laboratory and disease management. We urge advocacy for increased funding for domestic and global TB control programs, including expanded access to sputum culture and drug susceptibility testing, as well as funding for TB clinical trials and research capacity. We believe that substandard TB diagnostic tests are not acceptable for TB control in resource-poor countries. We urge the development of shorter, less toxic TB treatment and prevention regimens. Funding of TB control and research should be reassessed to prevent budget cuts at a time when the disease is killing as many as 2 million people a year.
Comment in: Clin Infect Dis. 2007 Nov 1;45(9):1247. (PMID: 17918097)
